Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Conditions Advanced Solid Tumor Bladder Cancer Breast Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gastric Cancer Head and Neck Cancer Lung Cancer Melanoma Non-small Cell Lung Cancer (NSCLC) Ovarian Carcinoma Pancreatic Carcinoma Prostate Cancer

Interventions HER3-DXd

Updated 17 times since 2024 Last updated: Jan 26, 2026 Started: Feb 26, 2024 Primary completion: Sep 1, 2027 Completion: Oct 10, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06172478, this PHASE2 trial focuses on Advanced Solid Tumor and Bladder Cancer and remains actively recruiting participants. Sponsored by Daiichi Sankyo, it has been updated 17 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

17 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2

▶ Show 12 earlier versions

Jul 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2024 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo
Merck Sharp & Dohme LLC

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Baltimore, United States , Barcelona, Spain , Bergamo, Italy , Bordeaux, France , Brussels, Belgium , Buffalo, United States , Camperdown, Australia , Chermside, Australia , Chicago, United States and 61 more locations